Entering text into the input field will update the search result below

Medtox Scientific beats first quarter estimates, 22% revenue growth

Apr. 14, 2011 9:55 AM ETMTOX
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Laboratory testing services provider Medtox Scientific (NASDAQ:MTOX) said Thursday that first quarter profits grew by eight times from the prior year period as revenues increased across all operating segments, topping market views.

For the three months ending March 31, the St. Paul, Minnesota-based company, which provides clinical and diagnostic testing services, posted net income of roughly $0.8 million, or $0.09 per diluted share, compared to approximately $0.1 million, or $0.01 per  share in the prior year period.

Total revenue rose by 22% to $25.7 million. Analysts were expecting earnings of $0.08 per share on revenue of $24.5 million.

In the core laboratory segment, the company's drugs-of-abuse testing services unit saw revenue increase 10% to $9.6 million, while clinical laboratory sales in the quarter jumped 16% to $8.0 million.

Clinical trial services sales improved by a whopping 204% to $2.5 million. Revenues from the diagnostic unit increased by 20%.

Gross margins were higher in both the laboratory services and diagnostic products segments, with overall gross margin increasing 230 basis points to 40.6%, compared to 38.3% in the first quarter of 2010.

At quarter-end, the company had cash on hand of $1.0 million and no long-term debt.

Medtox shares rose nearly 2% in pre-market trading on Thursday to $15.95.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.